These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33981733)

  • 1. Estimated Glomerular Filtration Rate Is Associated With an Increased Risk of Death in Heart Failure Patients With Preserved Ejection Fraction.
    Chen Z; Lin Q; Li J; Wang X; Ju J; Xu H; Shi D
    Front Cardiovasc Med; 2021; 8():643358. PubMed ID: 33981733
    [No Abstract]   [Full Text] [Related]  

  • 2. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
    Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease.
    Bansal N; Zelnick L; Bhat Z; Dobre M; He J; Lash J; Jaar B; Mehta R; Raj D; Rincon-Choles H; Saunders M; Schrauben S; Weir M; Wright J; Go AS;
    J Am Coll Cardiol; 2019 Jun; 73(21):2691-2700. PubMed ID: 31146814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
    O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
    Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
    Choy M; Zhen Z; Dong B; Chen C; Dong Y; Liu C; Liang W; Xue R
    ESC Heart Fail; 2023 Apr; 10(2):1214-1221. PubMed ID: 36695165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
    Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
    Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF.
    Zhou Y; Fu L; Sun J; Zhu Z; Xing Z; Zhou S; Tai S; Wang Y
    Front Cardiovasc Med; 2021; 8():698117. PubMed ID: 34595217
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Savarese G; Xu H; Trevisan M; Dahlström U; Rossignol P; Pitt B; Lund LH; Carrero JJ
    JACC Heart Fail; 2019 Jan; 7(1):65-76. PubMed ID: 30553905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction.
    Unger ED; Dubin RF; Deo R; Daruwalla V; Friedman JL; Medina C; Beussink L; Freed BH; Shah SJ
    Eur J Heart Fail; 2016 Jan; 18(1):103-12. PubMed ID: 26635076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.